These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1107224)

  • 21. Experimental cancer immunotherapy: comparison of tumor rejection if F344 rats given live Mycobacterium bovis (Strain BCG) and killed Corynebacterium parvum.
    Likhite VV
    J Natl Cancer Inst; 1976 May; 56(5):985-9. PubMed ID: 994209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic effect of Candida albicans and Staphylococcus aureus on mouse mortality.
    Carlson E
    Infect Immun; 1982 Dec; 38(3):921-4. PubMed ID: 7152678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morphogenesis is not required for Candida albicans-Staphylococcus aureus intra-abdominal infection-mediated dissemination and lethal sepsis.
    Nash EE; Peters BM; Palmer GE; Fidel PL; Noverr MC
    Infect Immun; 2014 Aug; 82(8):3426-35. PubMed ID: 24891104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of solid tumours by intratumoral injection of immunostimulants].
    Salomon JC; Lynch N
    Ann Immunol (Paris); 1977; 128(1-2):125-7. PubMed ID: 322574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of biological significance of in vitro Brugia malayi microfilarial cytotoxicity mediated by Propionibacterium acnes ("Corynebacterium parvum")-and Mycobacterium bovis BCG-activated macrophages.
    Fanning MM; Kazura JW
    Infect Immun; 1986 May; 52(2):534-7. PubMed ID: 3516877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection by Candida albicans of Staphylococcus aureus in the establishment of dual infection in mice.
    Carlson E; Johnson G
    Infect Immun; 1985 Dec; 50(3):655-9. PubMed ID: 3905609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro killing of schistosomula of Schistosoma mansoni by BCG and C. parvum-activated macrophages.
    Mahmoud AA; Peters PA; Civil RH; Remington JS
    J Immunol; 1979 May; 122(5):1655-7. PubMed ID: 376723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of immunotherapy with Corynebacterium parvum and methanol extraction residue of BCG administered intravenously on host defense function in cancer patients.
    Hersh EM; Murphy SG; Quesada JR; Gutterman JU; Gschwind CR; Morgan J
    J Natl Cancer Inst; 1981 Jun; 66(6):993-1002. PubMed ID: 6941048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparative studies of the immunostimulating (paramunizing) effectiveness of BCG, levamisole, Corynebacterium parvum and preparations of pock viruses in various in vivo and in vitro tests].
    Mayr A; Büttner M; Pawlas S; Erfle V; Mayr B; Brunner R; Osterkorn K
    Zentralbl Veterinarmed B; 1986 Jun; 33(5):321-39. PubMed ID: 2430381
    [No Abstract]   [Full Text] [Related]  

  • 30. Interferon production by Corynebacterium parvum and BCG-activated murine spleen macrophages.
    Neumann C; Macher E; Sorg C
    Immunobiology; 1980 Apr; 157(1):12-23. PubMed ID: 6162779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stimulation of the non-specific resistance by Corynebacterium parvum and Bacillus calmette Guérin.
    Ruitenberg EJ; Steerenberg PA
    Tijdschr Diergeneeskd; 1976 Jul; 101(14):775-8. PubMed ID: 821172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in normal mice.
    Wolmark N; Levine M; Fisher B
    J Reticuloendothel Soc; 1974 Oct; 16(4):252-7. PubMed ID: 4455907
    [No Abstract]   [Full Text] [Related]  

  • 33. Relationship between intradermal tumor suppression and tumor immunity.
    Bartlett GL; Kreider JW; Purnell DM
    J Natl Cancer Inst; 1976 Dec; 57(6):1297-303. PubMed ID: 794505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitory effect of prolonged Corynebacterium parvum and cyclophosphamide administration on the growth of established tumors.
    Fisher B; Wolmark N; Saffer E; Fisher ER
    Cancer; 1975 Jan; 35(1):134-43. PubMed ID: 1109767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Host immunological mechanisms in the resistance of mice to leptospiral infections.
    Adler B; Faine S
    Infect Immun; 1977 Jul; 17(1):67-72. PubMed ID: 885617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of anti-thymocyte serum, anti-macrophage serum, and latex particles on the therapeutic efficacy of BCG or Corynebacterium liquefaciens (Propionibacterium acnes C7) in syngeneic mice.
    Tanaka T; Nakagawa H; Kato A; Yoshimura M; Fujita H; Kimura K
    Gan; 1977 Feb; 68(1):45-52. PubMed ID: 324858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor activity of intralesionally administered Nocardia opaca preparations in rat and mouse tumors: a comparison with BCG and Corynebacterium parvum.
    Barot-Ciorbaru R; Petit JF; Chassoux D; Salomon JC
    Int J Immunopharmacol; 1981; 3(2):115-22. PubMed ID: 7021434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer.
    Bjornsson S; Takita H; Kuberka N; Preisler H; Catane H; Higby D; Henderson E
    Cancer Treat Rep; 1978 Apr; 62(4):505-10. PubMed ID: 350388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the effect of viral paramunity inducers PIND-AVI and PIND-ORF with that of BCG, Corynebacterium parvum and levamisole on the growth of radiation-induced murine osteosarcoma.
    Müller-Brunecker G; Erfle V; Mayr A
    Zentralbl Veterinarmed B; 1986 Apr; 33(3):188-95. PubMed ID: 3463079
    [No Abstract]   [Full Text] [Related]  

  • 40.
    Sheehan G; Tully L; Kavanagh KA
    Microbiology (Reading); 2020 Apr; 166(4):375-385. PubMed ID: 32068530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.